Autonomous Cortisol Secretion in Patients with Primary Aldosteronism: Prevalence and Implications on Cardiometabolic Profile and on Surgical Outcomes

Purpose: The aim of this study was to evaluate the prevalence of autonomous cortisol secretion (ACS) in patients with primary aldosteronism (PA) and its implications on cardiometabolic and surgical outcomes.

Methods: This is a retrospective multicenter study of PA patients who underwent 1 mg dexamethasone-suppression test (DST) during diagnostic workup in 21 Spanish tertiary hospitals. ACS was defined as a cortisol post-DST >1.8 µg/dL (confirmed ACS if >5 µg/dL and possible ACS if 1.8-5 µg/dL) in the absence of specific clinical features of hypercortisolism. The cardiometabolic profile was compared with a control group with ACS without PA (ACS group) matched for age and DST levels.

Results: The prevalence of ACS in the global cohort of patients with PA (n = 176) was 29% (ACS-PA; n = 51). Ten patients had confirmed ACS and 41 possible ACS. The cardiometabolic profile of ACS-PA and PA-only patients was similar, except for older age and larger tumor size of the adrenal lesion in the ACS-PA group. When comparing the ACS-PA group (n = 51) and the ACS group (n = 78), the prevalence of hypertension (OR 7.7 (2.64-22.32)) and cardiovascular events (OR 5.0 (2.29-11.07)) was higher in ACS-PA patients than in ACS patients. The coexistence of ACS in patients with PA did not affect the surgical outcomes, the proportion of biochemical cure and clinical cure being similar between ACS-PA and PA-only groups.

Conclusion: Co-secretion of cortisol and aldosterone affects almost one-third of patients with PA. Its occurrence is more frequent in patients with larger tumors and advanced age. However, the cardiometabolic and surgical outcomes of patients with ACS-PA and PA-only are similar.

Citing Articles

Impact of Cortisol-Cosecretion on Adrenal Venous Sampling Results in Primary Aldosteronism: Study of 225 Cases.

Lamas C, Araujo-Castro M, Ostermair L, Petersenn E, Parra Ramirez P, Rebollo-Roman A Biomedicines. 2024; 12(11).

PMID: 39594996 PMC: 11591640. DOI: 10.3390/biomedicines12112430.

Epidemiology and Management of Hypertension and Diabetes Mellitus in Patients with Mild Autonomous Cortisol Secretion: A Review.

Araujo-Castro M, Reincke M, Lamas C Biomedicines. 2023; 11(12).

PMID: 38137336 PMC: 10740610. DOI: 10.3390/biomedicines11123115.

References

Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View

Katabami T, Matsuba R, Kobayashi H, Nakagawa T, Kurihara I, Ichijo T . Primary aldosteronism with mild autonomous cortisol secretion increases renal complication risk. Eur J Endocrinol. 2022; 186(6):645-655. DOI: 10.1530/EJE-21-1131. View

Williams T, Lenders J, Mulatero P, Burrello J, Rottenkolber M, Adolf C . Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017; 5(9):689-699. PMC: 5572673. DOI: 10.1016/S2213-8587(17)30135-3. View

Araujo-Castro M, Robles Lazaro C, Parra Ramirez P, Garcia Centeno R, Gracia Gimeno P, Fernandez-Ladreda M . Maximum adenoma diameter, regardless of uni- or bilaterality, is a risk factor for autonomous cortisol secretion in adrenal incidentalomas. J Endocrinol Invest. 2021; 44(11):2349-2357. DOI: 10.1007/s40618-021-01539-y. View

Di Dalmazi G, Vicennati V, Garelli S, Casadio E, Rinaldi E, Giampalma E . Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study. Lancet Diabetes Endocrinol. 2014; 2(5):396-405. DOI: 10.1016/S2213-8587(13)70211-0. View

Monticone S, Sconfienza E, DAscenzo F, Buffolo F, Satoh F, Sechi L . Renal damage in primary aldosteronism: a systematic review and meta-analysis. J Hypertens. 2019; 38(1):3-12. DOI: 10.1097/HJH.0000000000002216. View

Fallo F, Bertello C, Tizzani D, Fassina A, Boulkroun S, Sonino N . Concurrent primary aldosteronism and subclinical cortisol hypersecretion: a prospective study. J Hypertens. 2011; 29(9):1773-7. DOI: 10.1097/HJH.0b013e32834937f3. View

Araujo-Castro M, Paja Fano M, Gonzalez Boillos M, Peris B, Pascual-Corrales E, Garcia Cano A . Predictive model of hypertension resolution after adrenalectomy in primary aldosteronism: the SPAIN-ALDO score. J Hypertens. 2022; 40(12):2486-2493. DOI: 10.1097/HJH.0000000000003284. View

Geller D, Zhang J, Wisgerhof M, Shackleton C, Kashgarian M, Lifton R . A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab. 2008; 93(8):3117-23. PMC: 2515083. DOI: 10.1210/jc.2008-0594. View

10.

Hanslik G, Wallaschofski H, Dietz A, Riester A, Reincke M, Allolio B . Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn's Registry. Eur J Endocrinol. 2015; 173(5):665-75. DOI: 10.1530/EJE-15-0450. View

11.

Bhatt P, Sam A, Meeran K, Salem V . The relevance of cortisol co-secretion from aldosterone-producing adenomas. Hormones (Athens). 2019; 18(3):307-313. PMC: 6797639. DOI: 10.1007/s42000-019-00114-8. View

12.

Gendreitzig P, Kunzel H, Adolf C, Handgriff L, Muller L, Holler F . Autonomous Cortisol Secretion Influences Psychopathological Symptoms in Patients With Primary Aldosteronism. J Clin Endocrinol Metab. 2021; 106(6):e2423-e2433. DOI: 10.1210/clinem/dgab099. View

13.

Harris P, Taylor R, Minor B, Elliott V, Fernandez M, ONeal L . The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019; 95:103208. PMC: 7254481. DOI: 10.1016/j.jbi.2019.103208. View

14.

Fallo F, Castellano I, Gomez-Sanchez C, Rhayem Y, Pilon C, Vicennati V . Histopathological and genetic characterization of aldosterone-producing adenomas with concurrent subclinical cortisol hypersecretion: a case series. Endocrine. 2017; 58(3):503-512. PMC: 5638684. DOI: 10.1007/s12020-017-1295-4. View

15.

Desrochers M, St-Jean M, El Ghorayeb N, Bourdeau I, So B, Therasse E . Basal contralateral aldosterone suppression is rare in lateralized primary aldosteronism. Eur J Endocrinol. 2020; 183(4):399-409. DOI: 10.1530/EJE-20-0254. View

16.

Peng K, Liao H, Chan C, Lin W, Yang S, Tsai Y . Presence of Subclinical Hypercortisolism in Clinical Aldosterone-Producing Adenomas Predicts Lower Clinical Success. Hypertension. 2020; 76(5):1537-1544. DOI: 10.1161/HYPERTENSIONAHA.120.15328. View

17.

Tsai C, Liao C, Wu X, Chen Z, Pan C, Chang Y . Autonomous cortisol secretion is associated with worse arterial stiffness and vascular fibrosis in primary aldosteronism: a cross-sectional study with follow-up data. Eur J Endocrinol. 2022; 187(1):197-208. DOI: 10.1530/EJE-21-1157. View

18.

Winzinger E, Jandikova H, Haase M, Knauerhase A, Winzinger T, Schott M . DHEAS and Differential Blood Counts as Indirect Signs of Glucocorticoid Excess in Adrenal Non-Producing Adenomas. Horm Metab Res. 2021; 53(8):512-519. DOI: 10.1055/a-1539-6442. View

19.

Spath M, Korovkin S, Antke C, Anlauf M, Willenberg H . Aldosterone- and cortisol-co-secreting adrenal tumors: the lost subtype of primary aldosteronism. Eur J Endocrinol. 2011; 164(4):447-55. DOI: 10.1530/EJE-10-1070. View

20.

Vassilatou E, Vryonidou A, Michalopoulou S, Manolis J, Caratzas J, Phenekos C . Hormonal activity of adrenal incidentalomas: results from a long-term follow-up study. Clin Endocrinol (Oxf). 2008; 70(5):674-9. DOI: 10.1111/j.1365-2265.2008.03492.x. View